Martek Biosciences has reached a settlement with Capsugel France that will see the supplement maker purchase all its algal DHA exclusively from Martek.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The news draws to a close Martek’s patent infringement action, which was filed in the High Court of Strasbourg, France, last year.
Additionally, Martek and Capsugel will jointly develop a product containing Martek’s algal DHA in Capsugel’s proprietary Licaps liquid-filled hard capsules, the companies revealed.
This settlement agreement between Martek and Capsugel does not include Martek’s action against Lonza, which continues, Martek said.

US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData